| Active substance |
Pramipexole |
| Also known as |
Pramipexole dihydrochloride |
| Blood pressure |
May cause orthostatic hypotension (drop in blood pressure when standing up) |
| Chemical name |
(S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine monohydrochloride |
| Dosage (medical) |
Initial dose is typically 0.125 mg three times a day, may be increased gradually based on patient response and tolerability |
| Dosage (sports) |
Not applicable as it is not used for athletic enhancement |
| Effects |
Improves motor control, reduces rigidity and tremors in Parkinson's patients |
| Formula |
C10H17N3S В· HCl |
| Half-life |
8-12 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Not typically required for monitoring |
| Main action |
Mimics dopamine in the brain, used to treat symptoms of Parkinson’s disease |
| Side effects |
Nausea, dizziness, hallucinations, insomnia, constipation, impulse control disorders |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Substance class |
Dopamine agonist |
| Trade name |
Mirapex, Mirapex ER |
| Use in sports |
None, not recognized as a performance enhancing drug |
| Water Retention |
Minimal to none |
| Manufacturer |
DEVA |
| Packing |
100 tabs (0,25mg/tab) |
